ATE189960T1 - Teil der konstanten region von ige enthaltender impfstoff zur behandlung ige-induzierter allergischer reaktionen - Google Patents

Teil der konstanten region von ige enthaltender impfstoff zur behandlung ige-induzierter allergischer reaktionen

Info

Publication number
ATE189960T1
ATE189960T1 AT92920757T AT92920757T ATE189960T1 AT E189960 T1 ATE189960 T1 AT E189960T1 AT 92920757 T AT92920757 T AT 92920757T AT 92920757 T AT92920757 T AT 92920757T AT E189960 T1 ATE189960 T1 AT E189960T1
Authority
AT
Austria
Prior art keywords
ige
vaccine
pct
mediated
antibodies
Prior art date
Application number
AT92920757T
Other languages
English (en)
Inventor
Lars T Hellman
Original Assignee
Lars T Hellman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20383848&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE189960(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lars T Hellman filed Critical Lars T Hellman
Application granted granted Critical
Publication of ATE189960T1 publication Critical patent/ATE189960T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/805—Drug, bio-affecting and body treating compositions involving IgE or IgD
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/862—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgE or IgD
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT92920757T 1991-09-26 1992-09-25 Teil der konstanten region von ige enthaltender impfstoff zur behandlung ige-induzierter allergischer reaktionen ATE189960T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9102808A SE9102808L (sv) 1991-09-26 1991-09-26 Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
PCT/SE1992/000673 WO1993005810A1 (en) 1991-09-26 1992-09-25 VACCINE COMPRISING PART OF CONSTANT REGION OF IgE FOR TREATMENT OF IgE-MEDIATED ALLERGIC REACTIONS

Publications (1)

Publication Number Publication Date
ATE189960T1 true ATE189960T1 (de) 2000-03-15

Family

ID=20383848

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92920757T ATE189960T1 (de) 1991-09-26 1992-09-25 Teil der konstanten region von ige enthaltender impfstoff zur behandlung ige-induzierter allergischer reaktionen

Country Status (16)

Country Link
US (1) US5653980A (de)
EP (1) EP0666760B2 (de)
JP (2) JP3583421B2 (de)
KR (1) KR100263359B1 (de)
AT (1) ATE189960T1 (de)
AU (1) AU677573B2 (de)
CA (1) CA2117193C (de)
DE (1) DE69230733T3 (de)
DK (1) DK0666760T4 (de)
ES (1) ES2144424T5 (de)
FI (1) FI107880B (de)
GR (1) GR3033272T3 (de)
HU (1) HU218899B (de)
RU (1) RU2120805C1 (de)
SE (1) SE9102808L (de)
WO (1) WO1993005810A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
AU707083B2 (en) * 1993-08-26 1999-07-01 Bavarian Nordic Inc. Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes
ATE164079T1 (de) * 1994-01-18 1998-04-15 Genentech Inc Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten
FR2715304B1 (fr) * 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Vaccin anti-allergique.
DE69718150T3 (de) * 1996-03-01 2009-03-05 Novartis Ag Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
US7118750B1 (en) * 1997-04-15 2006-10-10 Pharmexa A/S Modified TNF-alpha molecules, DNA encoding such and vaccines comprising such modified TNF-alpha and DNA
US6504013B1 (en) 2000-02-01 2003-01-07 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
US6734287B1 (en) 1998-04-09 2004-05-11 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
EP1621209A3 (de) * 1998-11-02 2006-04-19 Resistentia Pharmaceuticals AB Vakzinen die auf Domänen von chimären Immunoglobulin E Peptide basieren
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
US6511814B1 (en) 1999-03-26 2003-01-28 Idexx Laboratories, Inc. Method and device for detecting analytes in fluids
US6602719B1 (en) 1999-03-26 2003-08-05 Idexx Laboratories, Inc. Method and device for detecting analytes in fluids
EP1967205B1 (de) * 2000-08-30 2012-10-10 Pfizer Products Inc. Anti-IgE Vakzine
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
EP1497654A4 (de) * 2001-08-13 2006-06-07 Chen Swey Shen Alex Immunoglobulin-e-vakzine und verwendungsverfahren dafür
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
AU2003297953B2 (en) * 2002-09-05 2009-02-26 Resistentia Pharmaceuticals Ab Allergy vaccines
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
HUE030269T2 (en) 2006-06-26 2017-04-28 Macrogenics Inc FC RIIB-specific antibodies and methods for their use
US20080118524A1 (en) * 2006-10-20 2008-05-22 Stefan Persson Anti-IgE Vaccines
KR101634058B1 (ko) * 2008-12-09 2016-06-27 화이자 백신스 엘엘씨 ＩｇＥ ＣＨ３ 펩티드 백신
CN104667271B (zh) * 2009-02-25 2018-01-05 中央研究院 能与人B淋巴细胞上的mIgE结合的抗CεmX抗体
EP2942061A3 (de) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige-ch3-peptidimpfstoff
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
US9587034B2 (en) 2012-04-20 2017-03-07 Academia Sinica Anti-mIgE antibodies that bind to the junction between CH4 and CεmX domains
JP5918851B2 (ja) * 2012-06-18 2016-05-18 日本全薬工業株式会社 ＩｇＥペプチドワクチン
WO2015002985A2 (en) * 2013-07-01 2015-01-08 University Of Maryland Fc coupled compositions and methods of their use
MX2020004469A (es) 2017-10-31 2020-09-07 Oneness Biotech Co Ltd Tratamiento de enfermedades alergicas mediadas por ige.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8616166D0 (en) * 1986-07-02 1986-08-06 Research Corp Ltd Polypeptide competitor
GB8727045D0 (en) * 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
AU618317B2 (en) * 1987-12-31 1991-12-19 Tanox Biosystems, Inc. Unique antigenic epitopes on ige-bearing b lymphocytes
GB8910263D0 (en) * 1989-05-04 1989-06-21 Ciba Geigy Ag Monoclonal antibodies specific for an immunoglobulin isotype
GB8913737D0 (en) * 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment

Also Published As

Publication number Publication date
FI107880B (fi) 2001-10-31
ES2144424T3 (es) 2000-06-16
KR100263359B1 (ko) 2000-08-01
WO1993005810A1 (en) 1993-04-01
CA2117193A1 (en) 1993-04-01
RU2120805C1 (ru) 1998-10-27
HU218899B (hu) 2000-12-28
US5653980A (en) 1997-08-05
SE9102808L (sv) 1993-03-27
JP2004231663A (ja) 2004-08-19
AU677573B2 (en) 1997-05-01
HUT69782A (en) 1995-09-28
DK0666760T4 (da) 2008-01-21
DK0666760T3 (da) 2000-07-31
HU9400845D0 (en) 1994-06-28
SE9102808D0 (sv) 1991-09-26
JP3583421B2 (ja) 2004-11-04
CA2117193C (en) 2008-06-17
FI941193A (fi) 1994-03-14
DE69230733D1 (de) 2000-04-06
JPH06510768A (ja) 1994-12-01
EP0666760A1 (de) 1995-08-16
GR3033272T3 (en) 2000-09-29
DE69230733T2 (de) 2000-08-03
AU2676592A (en) 1993-04-27
FI941193A0 (fi) 1994-03-14
ES2144424T5 (es) 2008-03-01
EP0666760B1 (de) 2000-03-01
DE69230733T3 (de) 2008-05-21
EP0666760B2 (de) 2007-10-10

Similar Documents

Publication Publication Date Title
DE69230733D1 (de) Teil der konstanten region von ige enthaltender impfstoff zur behandlung ige-induzierter allergischer reaktionen
PT815235E (pt) Vacinas para peste
DK0654085T3 (da) Monomere og dimere antistof-fragment-fusionsproteiner
WO1996012794A3 (en) Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity
DE69130289T2 (de) Therapeutische verwendung von actin-bindenden verbindungen
ATE545652T1 (de) Reinigung und stabilisierung von proteinen und peptiden in pharmaceutischen agentien
DE69231576D1 (de) Verwendung von Peptiden ZUR BEHANDLUNG VON KOMPLIKATIONEN UND PATHOLOGY BEI DIABETES
DE602004025668D1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
KR920700667A (ko) 세포간 점착분자 및 그의 결합리간드의 천식치료에의 이용
Jones et al. A novel Fab-based antivenom for the treatment of mass bee attacks.
DE69031563D1 (de) Behandlung der autoimmunen uveoretinitis in menschen
ATE258799T1 (de) Verwendung einer chemisch stabilisierten chloritlösung zur inhibition der antigenspezifischen immunantwort
DE69428272D1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
ATE366118T1 (de) Verwendung von immuntherapeutischem wirkstoff auf peptidbasis
ES2319341T3 (es) Fragmentos tolerogenicos de alergenos naturales.
DE69723982D1 (de) Behandlung des partiellen wachstumshormon-unempfindlichkeitssyndroms
DK0653939T3 (da) Anvendelse af en Hymenoptera-gift til fremstilling af et medikament til behandling af DNA-virusinfektioner
King Immunochemical studies of stinging insect venom allergens
ATE202114T1 (de) Verwendung von peptiden welche eine immunantwort bewirken zur herstellung von medikamenten zur induzierung der immunsuppression.
Wu et al. Immunoblot analysis of allergens in crude mosquito extracts
DE69637943D1 (de) LO-CD2a Antikörper und deren Verwendung zur Hemmung der T-zellen Aktivierung und Proliferation
DE69529920T2 (de) Peptide des pferdearteritisvirus, antikörper und ihre verwendung in einem diagnostischen test
ES2062502T3 (es) Una proteina de factor i pura y un procedimiento para obtener dicha proteina.
Ruben Recombinant DNA produced human IL-2, injected in vivo, will substitute for carrier priming of helper function in the South African clawed toad, Xenopus laevis
Axelsson et al. A case of angioneurotic oedema with a high content of non-functioning, double peaked C1 esterase inhibitor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 0666760

Country of ref document: EP

REN Ceased due to non-payment of the annual fee